Corticosteroid-Associated Cardiac Arrhythmias

Dose-Dependent Arrhythmia Risk

High-dose corticosteroid use (≥7.5 mg prednisone equivalents) increases atrial fibrillation risk dramatically (OR 6.07; 95% CI 3.90-9.42) 1
The risk is greatest at treatment initiation and with short-term high-dose use 2, 1

Dexamethasone 10 mg = Methylprednisolone 48 mg = Prednisone 60 mg 3
Dexamethasone is approximately 5 times more potent than methylprednisolone 3
Standard dexamethasone dosing (e.g., 20 mg for chemotherapy-induced nausea) easily exceeds the high-risk threshold when converted to prednisone equivalents 4

Atrial fibrillation risk increases 2.49-fold (95% CI 1.56-3.97) with oral corticosteroid use 2, 1

Direct increase in cellular K+ efflux shortens atrial action potential duration and effective refractory period 2, 1
Mineralocorticoid-like effects increase plasma volume, elevating atrial pressures and promoting atrial enlargement 2, 1
Long-term use promotes atherosclerosis, diabetes, hypertension, and heart failure—all independent AF risk factors 2, 1

Highest risk patients requiring cardiac monitoring are those receiving high-dose IV pulse therapy (≥500 mg methylprednisolone or equivalent) 5

No evidence supports choosing one corticosteroid over another specifically to reduce arrhythmia risk 2, 1
Selection should be based on indication-specific guidelines (e.g., dexamethasone preferred for chemotherapy-induced nausea, either agent acceptable for inflammatory conditions) 4, 3
When equivalent efficacy exists, prednisone may be preferred in pediatric populations due to concerns about dexamethasone's higher potency and associated risks in certain age groups 6

Underestimating cumulative corticosteroid exposure: Multiple "low-dose" dexamethasone courses may exceed high-risk thresholds when calculated as prednisone equivalents 6
The increased AF risk disappears after corticosteroid discontinuation, so current exposure is what matters 2, 1

The American College of Cardiology notes that prednisone has documented anti-arrhythmic properties in specific inflammatory conditions, such as pericarditis and cardiac sarcoidosis, where it can suppress atrial fibrillation susceptibility and reduce C-reactive protein concentrations 7, 8
In patients with inflammatory cardiac conditions, such as pericarditis and cardiac sarcoidosis, prednisone may reduce atrial fibrillation burden by treating the underlying inflammatory substrate, with the American College of Cardiology citing evidence from studies on canine pericarditis and atrial tachypacing models 7, 8